Obesity
| Treatments
Obesity
Treatments
Sex, Age and BMI Predict Weight Loss Response to the GIP/GLP-1/Glucagon Receptor Agonist Retatrutide
book_2
Source:
ObesityWeek 2023 - Oral presentation
calendar_today
Published on Medfyle:
November 2023
import_contacts
4
min
In this medfyle
Response to retatrutide as treatment for obesity was significantly greater for women than men, more severe obesity, and younger people.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a summary of a presentation given at the ObesityWeek®️ 2023.
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content.
©️2023 Infomedica-Medfyle. All rights reserved.
